Table 1.
Baseline demographic characteristics of study population.
| Patient characteristics | Value |
|---|---|
| Gender, M, n (%) | 48 (44) |
| Age, year, mean ± SD | 57.3 ± 14.4 |
| Hypertension, n (%) | 49 (45) |
| DM, n (%) | 32 (29.4) |
| CAD, n (%) | 24 (22) |
| HFrEF or HFpEF, n (%) | 10 (9.2) |
| COPD, n (%) | 22 (20.2) |
| Cancer or taking chemoprophylaxis, n (%) |
2 (1.8) |
Tisdale risk score, n (%)
|
93 (85.3) 12 (11) 4 (3.6) |
| Medications which | |
| ACEI or ARB, n (%) | 31 (28.4) |
| CCB, n (%) | 22 (20.2) |
| Diuretics, n (%) | 27 (24.8) |
| Ivabradine, n (%) | 0 (0) |
| Ranolazine, n (%) | 1 (0.9) |
| Amiodarone, n (%) | 1 (0.9) |
| Propafenone, n (%) | 0 (0) |
| Favipiravir, n (%) | 31 (28.4) |
| Oseltamivir. n (%) | 68 (62.4) |
| SSRI, n (%) | 7 (6.4) |
| Tocilizumab, n (%) | 2 (1.8) |
ACEI- angiotensin converting enzyme inhibitory; ARB- angiotensin receptor blocker; CAD- coronary artery disease; CCB- calcium channel blocker; COPD- chronic obstructive pulmonary disease; DM- diabetes mellitus; HFpEF- heart failure with preserved ejection fraction; HFrEF- heart failure with reduced ejection fraction; SSRI- selective serotonin receptor inhibitor;